Milestone Scientific 将来の成長

Future 基準チェック /16

Milestone Scientificは、12.9%と17.5%でそれぞれ年率12.9%で利益と収益が成長すると予測される一方、EPSはgrowで15.6%年率。

主要情報

12.9%

収益成長率

15.6%

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	17.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	20 Nov 2024

今後の成長に関する最新情報

Recent updates

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Feb 23

Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like

Dec 15

業績と収益の成長予測

NYSEAM:MLSS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	13	-3	N/A	N/A	1
12/31/2025	11	-4	N/A	0	2
12/31/2024	9	-5	N/A	-1	2
9/30/2024	9	-5	-3	-3	N/A
6/30/2024	8	-5	-3	-3	N/A
3/31/2024	9	-7	-5	-5	N/A
12/31/2023	10	-7	-5	-5	N/A
9/30/2023	10	-7	-5	-5	N/A
6/30/2023	10	-7	-5	-5	N/A
3/31/2023	9	-8	-7	-7	N/A
12/31/2022	9	-9	-6	-6	N/A
9/30/2022	9	-8	-5	-5	N/A
6/30/2022	9	-8	-6	-6	N/A
3/31/2022	10	-8	-5	-5	N/A
12/31/2021	10	-7	-4	-4	N/A
9/30/2021	10	-7	-4	-4	N/A
6/30/2021	9	-6	-5	-5	N/A
3/31/2021	7	-7	-7	-7	N/A
12/31/2020	5	-7	-7	-7	N/A
9/30/2020	6	-9	-7	-7	N/A
6/30/2020	6	-10	-5	-5	N/A
3/31/2020	8	-8	-3	-3	N/A
12/31/2019	8	-8	-2	-2	N/A
9/30/2019	10	-4	-1	-1	N/A
6/30/2019	10	-6	-1	-1	N/A
3/31/2019	10	-6	-1	-1	N/A
12/31/2018	10	-7	-2	-2	N/A
9/30/2018	8	-9	-2	-2	N/A
6/30/2018	9	-6	N/A	-2	N/A
3/31/2018	9	-7	N/A	-1	N/A
12/31/2017	11	-5	N/A	-1	N/A
9/30/2017	11	-5	N/A	-3	N/A
6/30/2017	11	-6	N/A	-3	N/A
3/31/2017	11	-6	N/A	-5	N/A
12/31/2016	10	-6	N/A	-5	N/A
9/30/2016	11	-6	N/A	-3	N/A
6/30/2016	11	-5	N/A	-4	N/A
3/31/2016	10	-6	N/A	-4	N/A
12/31/2015	9	-5	N/A	-3	N/A
9/30/2015	10	-5	N/A	-3	N/A
6/30/2015	10	-4	N/A	-2	N/A
3/31/2015	10	-2	N/A	-1	N/A
12/31/2014	10	-2	N/A	0	N/A
9/30/2014	10	1	N/A	1	N/A
6/30/2014	10	1	N/A	1	N/A
3/31/2014	10	2	N/A	2	N/A
12/31/2013	10	1	N/A	1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MLSS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MLSS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MLSS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MLSSの収益 ( 17.5% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: MLSSの収益 ( 17.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MLSSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Milestone Scientific 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 25%

Consensus revenue estimates decrease by 10%

Consensus revenue estimates decrease by 13%

Consensus EPS estimates fall by 29%, revenue upgraded

Consensus estimates of losses per share improve by 12%

Consensus forecasts updated

Recent updates

Consensus EPS estimates fall by 25%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. Announces CEO Changes

Milestone Scientific Expands Commercial Rollout of the CompuFlo Epidural System with Esteemed Pain Management Physician Dr. Elbaz At Hudson Specialty Care

Milestone Scientific Inc. Announces Commercial Rollout of Compuflo® Epidural System At Iheal Pain Center Following Medicare Price Assignment

Founder & Vice Chairman recently sold US$135k worth of stock

Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.031 loss in 2Q 2023)

Milestone Scientific Inc. Secures Key Patent Approvals in the U.S. and Europe

Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware

Milestone Scientific Inc. Announces Favorable Medicare Pricing for Its CompuFlo® Epidural System Within First JMAC Region Covering Florida

Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million.

New minor risk - Shareholder dilution

Milestone Scientific Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 13%

New major risk - Financial position

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Consensus EPS estimates fall by 29%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Milestone Scientific Inc. Announces Board Changes

Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors

Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022

Price target decreased to US$4.00

Price target decreased to US$4.00

Founder notifies of intention to sell stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Founder notifies of intention to sell stock

Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Founder exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020)

Founder exercised options to buy US$417k worth of stock.

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board recently sold US$86k worth of stock

Consensus EPS estimates fall to -US$0.11

Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020)

Chief Financial Officer Scott Kahn has left the company

Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index

Consensus forecasts updated

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020)

Consensus revenue estimates increase to US$10.3m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019)

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

New 90-day high: US$4.13

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Independent Chairman of the Board notifies of intention to sell stock

Analysts update estimates

Independent Chairman of the Board recently sold US$169k worth of stock